FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP
--

OMB APPROVAL										
OMB Number:	3235-0287									
Estimated average bu	ırden									
hours per response:	0.5									

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

Name and Address of Reporting Person* Meckler Jeffrey A				- 3.1	Susuer Name and Ticker or Trading Symbol Travere Therapeutics, Inc. [TVTX] Date of Earliest Transaction (Month/Day/Year)									Officer (give title			10% Owner Other (specify		
(Last)	`	,	(Middle)		05	05/08/2024									below)			below)	
C/O TRAVERE THERAPEUTICS, INC.				4. 1	4. If Amendment, Date of Original Filed (Month/Day/Year)							6. Individual or Joint/Group Filing (Check Applicable							
3611 VALLEY CENTRE DR., SUITE 300													Line) X	- /					
(Street)	EGO C.	Δ.	92130		_											•		One Repor	
SAN DII			92130		- R	Rule 10b5-1(c) Transaction Indication													
(City) (State) (Zip)					Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.														
		Tal	ole I - Nor	-Deri	ivativ	e Se	curitie	s Ac	quired,	Disp	osed o	f, or Be	nefic	ially	Owned				
1. Title of Security (Instr. 3) 2. Transa Date (Month/D					Execution Date		Transaction Disposed Code (Instr. 5)		rities Acquired (A) or ad Of (D) (Instr. 3, 4 an			5. Amour Securities Beneficia Owned Fe	es For ally (D) following (I) (Direct Indirect str. 4)	7. Nature of Indirect Beneficial Ownership			
							Code	v	Amount	(A) or (D)		се	Transacti (Instr. 3 a	on(s)			(Instr. 4)		
Common Stock ⁽¹⁾ 05/08/				08/202	8/2024		Α		6,5000	6,500 ⁽²⁾ A		\$ <mark>0</mark>	81,000			D			
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																			
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security (Instr. 3) 2. (Month/Day/Year) 3. Transaction Date Execution Date, if any (Month/Day/Year)				ate,	4. Transaction Code (Instr.		of		6. Date Exercisable and Expiration Date (Month/Day/Year)			7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)			3. Price of Derivative Security Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exercisable		Expiration Date	Title	Amor or Numl of Share	ber					
Stock option (right to buy) ⁽¹⁾	\$6.82	05/08/2024			A		19,500		05/08/2025	(2)	05/07/2034	Common Stock	19,5	000	\$0	19,500)	D	

Explanation of Responses:

- 1. Automatic equity grant under the Issuer's 2018 Equity Incentive Plan, as amended, pursuant to the non-employee director compensation program.
- 2. The equity award vests over a one year period.

/s/ Elizabeth E. Reed, Attorney-05/10/2024 in-Fact

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.